查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015230

胚胎著床前基因檢測市場：2026-2032年全球市場預測（依檢測類型、技術類型、交付方式、實施階段、應用程式和最終用戶分類）

Preimplantation Genetic Testing Market by Test Type, Technology Type, Offering, Procedure Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胚胎著床前基因檢測 (PGT) 市值將達到 8.7501 億美元，到 2026 年將成長至 9.8115 億美元，到 2032 年將達到 19.7849 億美元，年複合成長率為 12.36%。

主要市場統計數據
基準年 2025 8.7501億美元
預計年份：2026年 9.8115億美元
預測年份 2032 1,978,490,000 美元
複合年成長率 (%) 12.36%

對胚胎著床前基因檢測的引人入勝的展望，涵蓋臨床整合、技術成熟度和不斷變化的相關人員期望。

胚胎著床前遺傳學檢測（PGD）已從輔助生殖技術中的一種特殊輔助工具發展成為生殖遺傳學和個人化生殖醫學的核心要素。臨床醫生、檢查室管理者和醫療保健領導者現在都認知到，基因檢測對於胚胎選擇、降低單基因疾病風險以及最佳化臨床結果至關重要。在不斷變化的監管預期和保險公司態度的推動下，檢查室和診所面臨越來越大的壓力，需要確保診斷準確性、簡化工作流程，並向患者和轉診網路證明其臨床效用。

技術創新、不斷發展的臨床工作流程和監管改進如何重塑生殖遺傳學的檢測實踐和病患照護路徑？

隨著臨床、技術和監管領域各方力量的融合，胚胎著床前遺傳學檢測（PGD）領域正經歷一場變革。定序精度和生物資訊演算法的進步提高了胚胎遺傳評估的解析度，從而能夠更精確地檢測非整倍體、結構重排和單基因突變。因此，檢查室正從單一方法模式轉向結合高通量定序和標靶確認性檢測的混合工作流程，從而在應對成本和產能挑戰的同時，提高診斷可靠性。

對 2025 年關稅變化對診斷和生育服務提供者的供應鏈、籌資策略和業務永續營運的影響進行系統評估。

2025年關稅上調和貿易限制的實施，使得支撐基因檢測流程的跨境供應鏈面臨更嚴格的審查。進口關稅和累積關稅調整增加了專用設備、試劑和耗材的採購成本，給依賴國際供應商的診斷檢查室和生育中心帶來了即時的營運壓力。為此，許多機構正在重新審視籌資策略，優先選擇擁有強大的本地分銷網路和替代採購管道的供應商，以減輕關稅波動的影響。

將檢驗類別、調查方法、商業產品和最終用戶採用模式與策略重點連結的詳細細分分析。

細分市場分析揭示了不同檢測類型、形式、技術、產品和服務以及最終用戶群體在臨床和商業性趨勢上的差異。基於檢測類型，用於染色體異常檢測的 PGT-A、用於單基因疾病檢測的 PGT-M 以及用於結構重排檢測的 PGT-SR 之間的差異，凸顯了檢查室工作流程、諮詢需求和證據標準方面的不同。例如，PGT-M 計畫通常需要針對特定家族開發檢測方法，並與臨床遺傳學深度整合，而 PGT-A 工作流程則優先考慮高通量染色體異常篩檢和簡化的報告流程。基於檢測類型，胚胎著床前遺傳學診斷 (PGD) 和胚胎著床前遺傳學篩檢(PGS) 之間的區別，凸顯了臨床目標和患者諮詢方面的差異。診斷通常著重於已知的遺傳性變異和針對性解讀，而篩檢強調更廣泛的染色體評估和人群層面的風險分層。

區域法規結構、支付方環境和臨床部署模式如何塑造美洲、歐洲、中東和非洲以及亞太地區的差異化策略。

區域趨勢正在影響胚胎著床前遺傳學檢測 (PGD) 領域的服務提供模式和策略夥伴關係。在美洲，主要都市區的先進臨床部署與透過私人生育網路快速傳播的創新技術並存，從而形成了一個由專業檢測實驗室、轉診診所和學術合作機構組成的密集生態系統。相較之下，歐洲、中東和非洲的法規結構和支付模式則更為多樣化。高度先進的公立和私立中心分佈分散，而服務取得受限的地區也並存，這導致了跨境病患流動和集中式檢測服務的出現。這種區域差異正在推動更廣泛的檢測網路和標準化報告方法的發展，以滿足跨轄區的臨床需求。

企業策略與夥伴關係趨勢揭示了整合、專業化和協作如何重新定義診斷和服務供應商的競爭優勢

胚胎著床前遺傳學檢測 (PGD) 領域的企業級趨勢反映了垂直整合、策略專業化和協作生態系統的整合。一些機構專注於提供端到端解決方案，整合儀器、試劑和分析軟體，為生育診所和中心檢查室提供承包解決方案。而其他機構則專注於自身優勢領域，例如開發罕見單基因疾病檢測、高解析度結構變異檢測或用於變異解讀和報告的雲原生分析技術。同時，檢測服務供應商正在拓展臨床夥伴關係和轉診網路，以提供具有標準化品管和整合報告框架的外包檢測服務。

產業相關人員可以實施切實可行的策略，以增強證據產生、供應鏈韌性、資訊學整合和以病人為中心的服務提供。

產業領導者可以採取果斷措施來提升臨床相關性、業務永續營運和商業性差異化。首先，他們應優先投資於檢測方法檢驗和臨床證據，以證明產品在不同患者群體和臨床路徑中的真實效用。這些證據將推動臨床醫生採納產品，並更有效地向支付方和醫療採購負責人傳達產品價值。其次，他們應透過多元化採購、與區域分銷商建立合作關係以及製定庫存策略來建立具有韌性的供應鏈，從而降低關稅和地緣政治動盪帶來的風險。透過強調透明的總擁有成本和可預測的補貨，企業可以減少服務中斷並保障利潤率。

透明嚴謹的調查方法，結合專家的直接訪談、第二手資料的整合以及反覆檢驗，確保了可靠且可操作的見解。

本分析的調查方法結合了對專家的深入訪談以及對第二手資料的系統整合和反覆檢驗。深入研究包括對臨床檢查室管理人員、胚胎學家、遺傳諮詢師、採購負責人和監管專家進行詳細訪談，以了解實際操作、臨床決策因素和採購限制。這些質性研究結果輔以對主流檢測方法、分析表現特徵和工作流程整合挑戰的技術評估，並透過引用同行評審文獻和技術白皮書來確保方法論的嚴謹性。

策略、營運和臨床促進因素的明確整合，將決定基因檢測在生殖醫學中的持續引入和長期整合。

總之，胚胎著床前遺傳學檢測（PGD）正處於一個轉折點，技術成熟度、患者期望和實際情況在此交匯，重塑著服務的提供方式。實驗室和生育服務機構必須平衡高分析效能、可擴展的工作流程和穩健的供應鏈。不斷變化的法規環境和支付方的嚴格審查將使那些優先考慮嚴格檢驗、清晰的臨床證據和可證明的品管的機構受益。同時，對生物資訊學、解讀軟體和整合諮詢路徑的投資將在提供以患者為中心的護理和支持臨床醫生採用PGD方面發揮關鍵作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章胚胎著床前基因檢測市場：檢測類型

  • PGT-A（染色體異常）
  • PGT-M（原發性腺組織疾病）
  • PGT-SR（結構重建）
  • PGT-HLA（人類白血球抗原（HLA）相容性檢測）

第9章胚胎著床前基因檢測市場：依技術類型分類

  • 比較基因雜合反應
  • 螢光原位雜合反應
  • 次世代定序
  • 基於PCR的檢測
  • 單核苷酸多態性

第10章：胚胎著床前基因檢測市場：依產品/服務分類

  • 裝置
  • 試劑和耗材
    • 成套工具
    • 探測

第11章 依治療階段胚胎著床前基因檢測市場

  • 切片檢查
  • 極切片檢查
  • 胚囊切片

第12章胚胎著床前基因檢測市場：依應用領域分類

  • 染色體數目異常篩檢
  • 單基因疾病
  • 體外受精（IVF）的預後

第13章胚胎著床前基因檢測市場：依最終用戶分類

  • 診斷檢測實驗室
  • 不孕症治療診所
  • 醫院
  • 研究機構

第14章胚胎著床前基因檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章胚胎著床前基因檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章胚胎著床前基因檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國胚胎著床前基因檢測市場

第18章：中國胚胎著床前基因檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Techne Corporation
  • Bioarray SL
  • EUROPE IVF International sro
  • F. Hoffmann-La Roche AG
  • Genea Limited
  • GENETiKS
  • Illumina, Inc.
  • Invicta Genetics
  • Invitae Corporation
  • Juno Genetics, US Inc.
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Merck KGaA
  • Natera, Inc.
  • NextGen Genetics Holdings, LLC
  • Ovation Fertility
  • PacGenomics
  • PerkinElmer, Inc.
  • Progyny, Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Reproductive Genetic Innovations, LLC
  • SEQUENCE46, LLC
  • Sysmex Corporation
  • Takara Bio Inc.
  • The Cooper Companies Inc.
  • Thermo Fisher Scientific Inc.
  • Vitrolife Sweden AB
  • Yikon Genomics（Shanghai）Co., Ltd.
Product Code: MRR-030EE48515DA

The Preimplantation Genetic Testing Market was valued at USD 875.01 million in 2025 and is projected to grow to USD 981.15 million in 2026, with a CAGR of 12.36%, reaching USD 1,978.49 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 875.01 million
Estimated Year [2026] USD 981.15 million
Forecast Year [2032] USD 1,978.49 million
CAGR (%) 12.36%

A compelling orientation to preimplantation genetic testing that frames clinical integration, technological maturation, and evolving stakeholder expectations

Preimplantation genetic testing has moved from a specialized adjunct to assisted reproduction into a core element of reproductive genetics and personalized reproductive care. Clinicians, laboratory directors, and institutional leaders now evaluate genetic testing as an integral part of embryo selection, risk mitigation for monogenic disorders, and optimizing clinical outcomes. Against a backdrop of evolving regulatory expectations and shifting payer attitudes, laboratories and clinics face heightened pressure to ensure diagnostic accuracy, streamline workflows, and demonstrate clinical utility to both patients and referral networks.

Technological progress has compressed turnaround times and improved resolution, enabling more definitive clinical decision-making while opening new pathways for integration with bioinformatics and electronic health records. Concurrently, patient expectations around transparency, counseling, and access are reshaping service delivery models; patients increasingly demand clear explanations of test scope, limitations, and the downstream implications for reproductive choices. As a result, cross-functional collaboration among embryologists, genetic counselors, laboratory scientists, and informatics specialists has become essential for delivering clinically robust and ethically sound testing programs.

Looking ahead, stakeholder imperatives center on harmonizing clinical evidence with operational scalability. Laboratories and fertility providers must reconcile the need for high-throughput, reproducible assays with individualized patient care. At the same time, research institutions and diagnostic partners are expanding translational efforts to refine variant interpretation, validate novel assays, and expand testing indications. This introduction sets the stage for a deeper appraisal of the transformative shifts reshaping the preimplantation genetic testing landscape.

How converging technological innovations, evolving clinical workflows, and regulatory refinements are reshaping testing operations and patient pathways in reproductive genetics

The preimplantation genetic testing environment is undergoing transformative shifts driven by converging clinical, technological, and regulatory forces. Advances in sequencing accuracy and bioinformatic algorithms have increased the resolution of embryo genetic assessment, enabling more nuanced detection of aneuploidy, structural rearrangements, and single-gene variants. Consequently, laboratories are transitioning from single-method paradigms to hybrid workflows that combine high-throughput sequencing with targeted confirmatory assays, thereby improving diagnostic confidence while managing cost and throughput considerations.

Simultaneously, the clinical ecosystem is adapting to greater patient demand for comprehensive genetic insight coupled with clear counseling frameworks. Genetic counseling has become more central to the patient journey, facilitating informed decision-making and risk communication. In parallel, payers and health systems are beginning to scrutinize clinical value propositions more closely, which is prompting providers to collect outcomes data and demonstrate the real-world utility of testing strategies. Regulatory authorities are also refining oversight, with increased expectations for analytical and clinical validation, laboratory accreditation, and post-market surveillance of diagnostic assays.

Operationally, supply chain resilience and reagent standardization have moved to the forefront of laboratory planning, prompting investments in inventory management and diversified sourcing. At a higher level, strategic alliances between fertility clinics, diagnostic laboratories, and specialist software providers are accelerating to create vertically integrated solutions that combine laboratory services with analytics, reporting, and patient engagement. These transformative shifts are collectively reshaping how testing is delivered, reimbursed, and perceived by patients and clinicians alike.

Assessing the systemic consequences of 2025 tariff changes on supply chains, procurement strategies, and operational resilience across diagnostic and fertility providers

The introduction of elevated tariff measures and trade restrictions in 2025 has intensified scrutiny of cross-border supply chains that support genetic testing workflows. Import levies and cumulative tariff adjustments have increased landed costs for specialized instruments, reagents, and consumables, creating immediate operational pressure for diagnostic laboratories and fertility centers that depend on international suppliers. In response, many organizations have re-evaluated procurement strategies to prioritize suppliers with robust local distribution networks or alternative sourcing channels that mitigate exposure to tariff volatility.

These trade dynamics have cascading implications for capital investment and service delivery. Institutions contemplating new instrument acquisitions are weighing not only acquisition price but also long-term maintenance, spare parts availability, and reagent procurement risk. As a result, procurement cycles have elongated and capital allocation decisions have been re-prioritized to favor suppliers with transparent total cost of ownership and resilient logistics. Some providers have also accelerated efforts to aggregate purchasing across regional networks or enter into long-term supply agreements to stabilize pricing and availability.

Beyond procurement, tariffs have spurred renewed interest in nearshoring and regional manufacturing partnerships. Stakeholders are evaluating opportunities to localize component assembly or reagent production to reduce exposure to import duties and expedite replenishment lead times. At the same time, laboratories are investing in process optimization and assay robustness to reduce dependency on single-source reagents. In short, the cumulative impact of tariff changes in 2025 has heightened emphasis on supply chain agility, local partnership development, and procurement governance as fundamental elements of operational resilience.

In-depth segmentation insights that connect testing categories, methodological platforms, commercial offerings, and end-user adoption patterns to strategic priorities

Segmentation analysis reveals differentiated clinical and commercial dynamics across testing types, test formats, technologies, offerings, and end users. Based on testing type, distinctions among PGT-A for aneuploidy detection, PGT-M for monogenic disorders, and PGT-SR for structural rearrangements highlight divergent laboratory workflows, counseling needs, and evidentiary standards; for example, PGT-M programs often require intensive family-specific assay development and deep clinical-genetic integration, whereas PGT-A workflows prioritize high-throughput aneuploidy screening and streamlined reporting. Based on test type, the separation between preimplantation genetic diagnosis and preimplantation genetic screening underscores differences in clinical intent and patient counseling; diagnosis is typically focused on known familial variants and targeted interpretation, while screening emphasizes broader chromosomal assessment and population-level risk stratification.

Based on technology type, the competitive dynamics hinge on methodological trade-offs among comparative genomic hybridization, fluorescent in-situ hybridization, next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism arrays. Next-generation sequencing is increasingly favored for its scalability and resolution, yet PCR-based and SNP approaches retain roles in confirmatory testing and specific assay designs. Comparative genomic hybridization and FISH continue to be relevant for certain structural assessments and regulatory-validated workflows, especially where orthogonal confirmation is required. Based on offering, the ecosystem separates into instruments, reagents and consumables, and software; instruments drive capital expenditure and laboratory footprint decisions, reagents and consumables determine recurring operating costs and supply chain exposure, and software governs data interpretation, reporting, and integration with clinical systems. Based on end user, diagnostic laboratories, fertility clinics, hospitals, and research institutes exhibit variable adoption patterns; diagnostic laboratories prioritize standardized, high-throughput workflows and accreditation, fertility clinics focus on turnaround time and counseling integration, hospitals emphasize interdisciplinary coordination and inpatient pathways, and research institutes prioritize methodological innovation and validation pathways. Together, these segmentation lenses illuminate where clinical needs, operational constraints, and commercial opportunities intersect, enabling stakeholders to prioritize investments and partnerships aligned with their strategic capabilities.

How regional regulatory frameworks, payer environments, and clinical adoption patterns are shaping differentiated strategies in the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape both service delivery models and strategic partnerships across the preimplantation genetic testing landscape. Americas maintain a combination of advanced clinical adoption in major urban centers and rapid innovation diffusion through private fertility networks, which has led to a dense ecosystem of specialized laboratories, referral clinics, and academic collaborators. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer models; pockets of highly advanced public and private centers coexist with regions where access is constrained, driving cross-border patient mobility and centralized laboratory services. This regional heterogeneity encourages pan-regional laboratory networks and standardized reporting approaches to address cross-jurisdictional clinical needs.

Asia-Pacific exhibits heterogenous trajectories as well, with select markets demonstrating rapid scale-up of assisted reproductive services, strong private-sector investment, and increased local capability in genomics. At the same time, several markets in the region are investing in capacity-building and regulatory frameworks to support clinical validation and ethical oversight. Across all regions, differences in reimbursement landscapes, regulatory expectations, and cultural perspectives on reproductive genetics influence service models, patient counseling practices, and commercialization strategies. As a result, successful regional approaches blend localized clinical pathways with global best practices in quality management and evidence generation, enabling providers to deliver consistent, ethically grounded, and operationally sustainable testing services.

Corporate strategies and partnership dynamics revealing how integration, specialization, and collaboration are redefining competitive advantage across diagnostics and service providers

Company-level dynamics in the preimplantation genetic testing space reflect a mix of vertical integration, strategic specialization, and collaborative ecosystems. Some organizations have concentrated on end-to-end solutions that combine instrumentation, reagents, and interpretive software to deliver turnkey offerings for fertility clinics and centralized laboratories. Other players have focused on niche strengths such as assay development for rare monogenic disorders, high-resolution structural variant detection, or cloud-native analytics for variant interpretation and reporting. In parallel, laboratory service providers have expanded clinical partnerships and referral networks to offer outsourced testing with standardized quality controls and consolidated reporting frameworks.

Partnerships and alliance formation have emerged as a primary vector for capability expansion. Commercial agreements between diagnostic laboratories and fertility networks, as well as collaborations with software vendors for integrated reporting, have enabled faster market entry and reduced the need for duplicative capital investment. In addition, strategic investments in regulatory compliance and accreditation have become competitive differentiators for laboratories seeking to serve international referral markets. Mergers and acquisitions continue to reconfigure the competitive terrain, especially where scale affords supply chain leverage, broader test menus, and enhanced data assets for variant curation. Collectively, these company insights underscore the importance of aligning technical capabilities with clear commercial pathways and compliance infrastructure to sustain growth and clinical credibility.

Practical, high-impact strategies that industry stakeholders can implement to enhance evidence generation, supply chain resilience, informatics integration, and patient-centered service delivery

Industry leaders can take decisive actions to strengthen clinical relevance, operational resilience, and commercial differentiation. First, prioritize investment in assay validation and clinical evidence that demonstrate real-world utility across diverse patient cohorts and clinical pathways; such evidence supports stronger clinician adoption and more effective communication of value to payers and institutional buyers. Second, cultivate resilient supply chains through multi-source procurement, regional distributor partnerships, and inventory strategies that mitigate exposure to tariff-driven or geopolitical disruptions. By emphasizing transparent total cost of ownership and predictable replenishment, organizations can reduce service interruptions and protect margins.

Third, accelerate integration of robust bioinformatics and interpretive software to standardize reporting, improve turnaround time, and enhance variant curation workflows. Interoperability with electronic health records and laboratory information systems will be a significant factor in clinician acceptance and cross-disciplinary coordination. Fourth, embed genetic counseling into the patient pathway to ensure informed consent, appropriate expectation-setting, and patient-centered communication about test scope and limitations. Finally, pursue strategic alliances and partnership models that combine clinical expertise, laboratory scale, and data analytics to unlock synergies while preserving regulatory compliance. These actions, when implemented in concert, create a defensible position that addresses both near-term operational risks and longer-term strategic growth.

Transparent and rigorous research methodology combining primary expert interviews, secondary evidence synthesis, and iterative validation to ensure robust and actionable insights

The research methodology underpinning this analysis blends primary expert engagement with structured secondary synthesis and iterative validation. Primary research included in-depth interviews with clinical laboratory leaders, embryologists, genetic counselors, procurement officers, and regulatory specialists to capture operational realities, clinical decision drivers, and procurement constraints. These qualitative insights were complemented by technical assessments of prevailing assay methodologies, analytical performance characteristics, and workflow integration challenges, drawing on peer-reviewed literature and technical white papers to ensure methodological rigor.

Secondary synthesis involved systematic review of clinical guidelines, professional society statements, and regulatory advisories to align the analysis with current standards of practice and compliance expectations. Data triangulation was used to reconcile divergent inputs and to surface consistent patterns across respondent groups and documented sources. Finally, findings underwent internal peer review and scenario stress-testing to evaluate sensitivity to supply chain disruptions, tariff variations, and technology adoption trajectories. The combined methodology ensures that conclusions are grounded in both frontline operational experience and documented best practices, providing a reliable basis for decision-making and strategic planning.

A definitive synthesis of the strategic imperatives, operational challenges, and clinical enablers that will determine sustainable adoption and long-term integration of genetic testing in reproductive care

In synthesis, preimplantation genetic testing stands at an inflection point where technological maturation, patient expectations, and operational realities converge to reshape service delivery. Laboratories and fertility providers must balance the need for high analytical performance with scalable workflows and resilient supply chains. The evolving regulatory environment and payer scrutiny will reward organizations that prioritize rigorous validation, clear clinical evidence, and demonstrable quality controls. At the same time, investments in bioinformatics, interpretive software, and integrated counseling pathways will be decisive in delivering patient-centered care and supporting clinician adoption.

Strategically, stakeholders that pursue collaborative models-combining laboratory excellence, clinical partnerships, and software-enabled reporting-are best positioned to translate technical capability into sustainable clinical services. Moreover, pragmatic procurement and regional partnership strategies will mitigate exposure to trade disruptions and tariff-related cost pressures. Looking forward, the sector's ability to standardize quality metrics, improve variant interpretation, and communicate clinical utility effectively will determine its broader acceptance and long-term integration into reproductive health practice. These conclusions underscore the imperative for coordinated action across clinical, operational, and commercial domains to realize the full potential of preimplantation genetic testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preimplantation Genetic Testing Market, by Test Type

  • 8.1. PGT-A (Aneuploidy)
  • 8.2. PGT-M (Monogenic Disorders)
  • 8.3. PGT-SR (Structural Rearrangements)
  • 8.4. PGT-HLA (Human Leukocyte Antigen Matching)

9. Preimplantation Genetic Testing Market, by Technology Type

  • 9.1. Comparative Genomic Hybridization
  • 9.2. Fluorescent In-Situ Hybridization
  • 9.3. Next-Generation Sequencing
  • 9.4. PCR-Based Testing
  • 9.5. Single-Nucleotide Polymorphism

10. Preimplantation Genetic Testing Market, by Offering

  • 10.1. Instruments
  • 10.2. Reagents & Consumables
    • 10.2.1. Kits
    • 10.2.2. Probes

11. Preimplantation Genetic Testing Market, by Procedure Stage

  • 11.1. Embryo Biopsy
  • 11.2. Polar Body Biopsy
  • 11.3. Blastocyst Biopsy

12. Preimplantation Genetic Testing Market, by Application

  • 12.1. Aneuploidy Screening
  • 12.2. Monogenic Diseases
  • 12.3. IVF Prognosis

13. Preimplantation Genetic Testing Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Fertility Clinics
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Preimplantation Genetic Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Preimplantation Genetic Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Preimplantation Genetic Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Preimplantation Genetic Testing Market

18. China Preimplantation Genetic Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Bio-Techne Corporation
  • 19.8. Bioarray S.L.
  • 19.9. EUROPE IVF International s.r.o.
  • 19.10. F. Hoffmann-La Roche AG
  • 19.11. Genea Limited
  • 19.12. GENETiKS
  • 19.13. Illumina, Inc.
  • 19.14. Invicta Genetics
  • 19.15. Invitae Corporation
  • 19.16. Juno Genetics, US Inc.
  • 19.17. Laboratory Corporation of America Holdings
  • 19.18. MedGenome Labs Ltd.
  • 19.19. Merck KGaA
  • 19.20. Natera, Inc.
  • 19.21. NextGen Genetics Holdings, LLC
  • 19.22. Ovation Fertility
  • 19.23. PacGenomics
  • 19.24. PerkinElmer, Inc.
  • 19.25. Progyny, Inc.
  • 19.26. Qiagen N.V.
  • 19.27. Quest Diagnostics Incorporated
  • 19.28. Reproductive Genetic Innovations, LLC
  • 19.29. SEQUENCE46, LLC
  • 19.30. Sysmex Corporation
  • 19.31. Takara Bio Inc.
  • 19.32. The Cooper Companies Inc.
  • 19.33. Thermo Fisher Scientific Inc.
  • 19.34. Vitrolife Sweden AB
  • 19.35. Yikon Genomics (Shanghai) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-HLA (HUMAN LEUKOCYTE ANTIGEN MATCHING), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY EMBRYO BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY EMBRYO BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY EMBRYO BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLAR BODY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLAR BODY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLAR BODY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY BLASTOCYST BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY BLASTOCYST BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY BLASTOCYST BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY MONOGENIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY IVF PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY IVF PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY IVF PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 180. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 181. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 188. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 189. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)